Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAIL-2: PRV-3279 in Systemic Lupus Erythematosus
NCT05087628Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Jan 2022
- Primary completion
- May 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of PRV-3279 in systemic lupus erythematosus (SLE), sponsored by Sanofi. Started Jan 2022; status: terminated.
02
Drugs
PRV-3279
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05087628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05087628.